Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Avacta Expands its Pipeline
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated October 17, 2024. It announces specific corporate news: 'Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform'. This is a typical structure for a press release or regulatory announcement disseminated via a news service like RNS (Regulatory News Service). The text details scientific developments (AVA6103 and AVA7100) and mentions upcoming presentations, which are standard components of a corporate update intended for the market. Since it is a general, time-sensitive announcement that doesn't fit the specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Change (CAP), and it is clearly a regulatory news item distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback.
2024-10-17 English
Avacta appoints Chief Scientific Officer
Board/Management Information Classification · 98% confidence The document is an official announcement released via RNS (RNS Number : 1444I) on October 15, 2024. The core content details the appointment of a new Chief Scientific Officer, Dr. Michelle Morrow. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is management change, making MANG the most precise classification over the general RNS fallback.
2024-10-15 English
Avacta Unveils Pipeline Expansion at EORTC 2024
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 6219H' and is dated '10 October 2024'. It announces that Avacta Group plc 'will present new preclinical data' at an upcoming symposium. The text is structured as a formal press release detailing scientific updates (pipeline expansion, novel therapies) and includes contact information for investor relations and brokers, concluding with standard RNS disclaimers. This format strongly indicates a general regulatory announcement released via the London Stock Exchange's RNS system, rather than a comprehensive financial report (10-K, IR) or a transcript (CT). Since it is a general regulatory announcement that doesn't fit the highly specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general regulatory filing category.
2024-10-10 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Results' announcement for Avacta Group plc for the six months ending 30 June 2024. It contains comprehensive financial highlights (revenue, R&D expenditure, EBITDA, loss per share, cash position), operational developments, and management commentary. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-09-30 English
Avacta Reported Updated Phase 1 Data of AVA6000
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '16 September 2024'. It details updated clinical trial data for a drug (AVA6000) presented at a medical congress (ESMO). The text concludes with contact information and a standard disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which is the definition of RNS (Regulatory Filings). While it contains detailed scientific and clinical information, its primary function here is as a formal regulatory disclosure via the RNS system, rather than a comprehensive financial report (10-K, IR) or a dedicated investor presentation (IP). Since it is a general regulatory announcement disseminated through the official channel, RNS is the most appropriate classification.
2024-09-16 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 8400D' and the closing boilerplate referencing RNS/LSE). The core content is a 'Notice of Results' stating that the company will announce its 'unaudited interim results on 30 September 2024' and will host an 'Investor Presentation' on the same day. Since the document is announcing the future release of results and the associated presentation/call, and it is short and regulatory in nature, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing the publication of results and the associated investor event, RPA is the most precise fit, as it signals the upcoming release of the IR/ER documents. However, since the document itself is a formal regulatory notification about the timing of results and a presentation, and it is not the results themselves, RPA (Report Publication Announcement) is the best fit, as it announces the publication of the results/presentation.
2024-09-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.